Aerosol pirfenidone and pyridone analog compounds and uses thereof
원문보기
IPC분류정보
국가/구분
United States(US) Patent
등록
국제특허분류(IPC7판)
A61K-031/573
A61K-009/00
A61M-011/02
A61M-011/00
출원번호
US-0495806
(2017-04-24)
등록번호
US-10028966
(2018-07-24)
발명자
/ 주소
Surber, Mark William
출원인 / 주소
AVALYN PHARMA INC.
대리인 / 주소
VLP Law Group, LLP
인용정보
피인용 횟수 :
0인용 특허 :
115
초록▼
Disclosed herein are formulations of pirfenidone or pyridone analog compounds for aerosolization and use of such formulations for aerosol administration of pirfenidone or pyridone analog compounds for the prevention or treatment of various fibrotic and inflammatory diseases, including disease associ
Disclosed herein are formulations of pirfenidone or pyridone analog compounds for aerosolization and use of such formulations for aerosol administration of pirfenidone or pyridone analog compounds for the prevention or treatment of various fibrotic and inflammatory diseases, including disease associated with the lung, heart, kidney, liver, eye and central nervous system. In some embodiments, pirfenidone or pyridone analog compound formulations and delivery options described herein allow for efficacious local delivery of pirfenidone or pyridone analog compound. Compositions include all formulations, kits, and device combinations described herein. Methods include inhalation procedures, indications and manufacturing processes for production and use of the compositions described.
대표청구항▼
1. A method of decreasing IL-1β levels in the lungs of a mammal diagnosed with pulmonary fibrosis comprising administering by inhalation an aqueous solution of pirfenidone to the mammal diagnosed with pulmonary fibrosis, wherein the pirfenidone solution consists of a prifenidone concentration from a
1. A method of decreasing IL-1β levels in the lungs of a mammal diagnosed with pulmonary fibrosis comprising administering by inhalation an aqueous solution of pirfenidone to the mammal diagnosed with pulmonary fibrosis, wherein the pirfenidone solution consists of a prifenidone concentration from about 0.1 mq/mL to about 20 mg/mL; sodium citrate; citric acid; sodium chloride; and sodium saccharin wherein the molar ratio of sodium saccharin to pirfenidone is between 1 to 53.9 and 1 to 215.9; wherein the osmolality of the aqueous solution is from about 200 mOsmol/kg to about 500 mOsmol/kg; and wherein the pH of the solution is about 5 to about 6, and wherein the administration of the aqueous solution to the mammal decreases IL-1β levels in the bronchial lavage fluid (BAL) of the mammal by at least 20%. 2. The method of claim 1, wherein the pulmonary fibrosis is idiopathic pulmonary fibrosis (IPF) or pulmonary fibrosis associated with systemic sclerosis, radiation exposure or transplant. 3. A method for the treatment of lung disease in a mammal comprising: administering by inhalation a dose of the aqueous solution of pirfenidone to the mammal in need thereof on a continuous dosing schedule, wherein the pirfenidone solution consists of a concentration of pirfenidone of from about 0.1 mg/mL to about 20 mg/mL; sodium citrate; citric acid; sodium chloride; and sodium saccharin wherein the molar ratio of sodium saccharin to pirfenidone is between 1 to 53.9 and 1 to 215.9; wherein the osmolality of the aqueous solution is from about 200 mOsmol/kg to about 500 mOsmol/kg; and wherein the pH of the solution is about 5 to about 6. 4. The method of claim 3, wherein the lung disease is idiopathic pulmonary fibrosis, or pulmonary fibrosis associated with systemic sclerosis, radiation exposure or transplant, lung cancer or pulmonary hypertension. 5. The method of claim 4, wherein the lung disease is lung cancer and the treatment comprises inhibiting, reducing or slowing the growth of lung tumor stroma. 6. The method of claim 3, wherein the aqueous solution is administered by inhalation to the mammal in need thereof with a liquid nebulizer. 7. The method of claim 6, wherein the liquid nebulizer is a jet nebulizer, an ultrasonic nebulizer, a pulsating membrane nebulizer, a nebulizer comprising a vibrating mesh or plate with multiple apertures, a nebulizer comprising a vibration generator and an aqueous chamber, or a nebulizer that uses controlled device features to assist inspiratory flow of the aerosolized aqueous solution to the lungs of the mammal. 8. The method of claim 7, wherein the liquid nebulizer: (i) after administration of the inhaled dose, achieves lung deposition of at least 7% of the pirfenidone administered to the mammal;(ii) provides a Geometric Standard Deviation (GSD) of emitted droplet size distribution of the aqueous solution of about 1.0 μm to about 2.5 μm;(iii) provides droplets of the aqueous solution emitted with the high efficiency liquid with: a) a mass median aerodynamic diameter (MMAD) of about 1 μm to about 5 μm;b) a volumetric mean diameter (VMD) of about 1 μm to about 5 μm; and/orc) a mass median diameter (MMD) of about 1 μm to about 5 μm;(iv) provides a fine particle fraction (FPF=%≤5 μm) of droplets emitted from the liquid nebulizer of at least about 30%;(v) provides an output rate of at least 0.1 mL/min; and/or(vi) provides at least about 25% of the aqueous solution to the mammal. 9. The method of claim 3, wherein the dose of the aqueous solution of pirfenidone is administered at least once a week. 10. The method of claim 3, wherein the dose of the aqueous solution of pirfenidone is administered on a continuous daily dosing schedule. 11. The method of claim 3, wherein the dose of the aqueous solution of pirfenidone is administered once a day, twice a day, three times a day, four times a day, five times a day, or six times a day. 12. The method of claim 3, wherein each dose of the aqueous solution of pirfenidone is administered within 20 minutes. 13. The method of claim 3, wherein the method further comprises administration of one or more additional therapeutic agents to the mammal.
연구과제 타임라인
LOADING...
LOADING...
LOADING...
LOADING...
LOADING...
이 특허에 인용된 특허 (115)
Gadekar Shreekrishna M. (Trenton NJ), 5-Methyl-1-phenyl-2-(1H)-pyridone compositions and methods of use.
James N. Schmidt CA; Jerry Grychowski ; Daniel K. Engelbreth CA; Robert Morton CA; Martin P. Foley CA, Aerosol medication delivery apparatus and system.
Hodson Peter D. (Trowell GB3) Baum Eric A. (Loughborough GB3) Smith David K. (Loughborough GB3) Kuepper Anton (Kaarst DEX) Wilby Matthew J. (Loughborough GB3), Breath actuated inhaler having an electromechanical priming mechanism.
Buchwald, Stephen L.; Klapars, Artis; Antilla, Jon C.; Job, Gabriel E.; Wolter, Martina; Kwong, Fuk Y.; Nordmann, Gero; Hennessy, Edward J., Copper-catalyzed formation of carbon-heteroatom and carbon-carbon bonds.
Newell Robert E. (Pinner GB2) Rand Paul K. (Nitchin GB2) Fitzsimmons Robert A. (Barnard Castle GB2), Devices for administering medicaments to patients.
Casper, Robert A.; Leith, Frank A.; Gardner, David L.; Snow, John M.; Lyon, Zachary W.; Farrar, David S., Dry powder medicament inhalator having an inhalation-activated flow diverting means for triggering delivery of medicament.
Mulhauser Paul (New York NY) Karg Jeffrey (Waldwick NY) Foxen Thomas (Brooklyn NY) Brooks Christopher J. (Glen Head NY), Dry powder medicament inhalator having an inhalation-activated piston to aerosolize dose and deliver same.
Humberstone Victor C. (Cambridge GBX) Newcombe Guy C. F. (Cambridge GBX) Sant Andrew J. (Cambridge GBX) Palmer Mathew R. (Cambridge GBX), Fluid droplets production apparatus and method.
Burns James S. (Darien CT) Marshak Daniel R. (Cold Spring Harbor NY), Inhalation device with a dose-timer, an actuator mechanism, and patient compliance monitoring means.
Ambrosio Thomas J. ; Ashley Charles R. ; Bilanin Alan J. ; Huck Charles M. ; Kaufman Andrew E. ; Kenyon David J. ; Manthena Srinivas ; Sochon Henry R. ; Wilkinson Ken ; Yang Tsong-Toh, Inhaler for powdered medications.
Seiwert, Scott; Beigelman, Leonid; Blatt, Lawrence M.; Kercher, Timothy; Kennedy, April L.; Andrews, Steven W., Inhibitors of hepatitis C virus replication.
Hess Joseph,CHX ; Bo Hu,CHX ; Weber Raphael,CHX ; Ortega Isabel,CHX ; Barraud Cedric,CHX ; van der Schoot Bart,CHX ; de Rooij Nicolaas Frans,CHX ; de Heij Bas,CHX, Liquid droplet spray device for an inhaler suitable for respiratory therapies.
Blatt,Lawrence M.; Andrews,Steven W.; Condroski,Kevin R.; Jiang,Yutong; Kennedy,April L.; Stengel,Peter J.; Wenglowsky,Steven M., Macrocyclic compounds as inhibitors of viral replication.
Zoltan Bart J. (Old Tappan NJ) Laube Beth L. (Baltimore MD) Adams ; III George K. (Baltimore MD) Bow Clark F. (Newton NJ) Devito Ralph J. (Stanhope NJ) Harrington Walter (Flanders NJ) Hoffman Louis S, Medication delivery system phase two.
Smith Adrian E. ; Burr John D. ; Etter Jeffery W. ; Axford George S. ; Lyons Shirley W. ; Platz Robert M., Method and apparatus for dispersion of dry powder medicaments.
Blatt, Lawrence M.; Seiwert, Scott D.; Beigelman, Leonid; Radhakrishnan, Ramachandran; Kossen, Karl; Serebryany, Vladimir, Method of modulating stress-activated protein kinase system.
Blineau Joseph (Rennes FRX) Pommier Daniel (Mordelles FRX) Thomas Claude (Chasne sur Illet FRX), Multiplex channels for continuous flow for numerical signal.
Nowacki Christopher (Arlington Heights IL) Brisson Alfred G. (Kildeer IL) Dela-Cruz Exequiel (Arlington Heights IL), Pediatric asthmatic medication inhaler.
Arnold Klaus (Ingelheim am Rhein DEX) Grass Peter (Ingelheim am Rhein DEX) Knecht Adolf (Freiburg DEX) Roos Robert (Ingelheim am Rhein DEX) Sluke Gerhard (Ingelheim am Rhein DEX) Thieme Herbet (Ingel, Powders for inhalation.
Hale, Ron L.; Lloyd, Peter M.; Lu, Amy T.; Rabinowitz, Joshua D.; Wensley, Martin J., Respiratory drug condensation aerosols and methods of making and using them.
※ AI-Helper는 부적절한 답변을 할 수 있습니다.